Loading asset research
Q2 2026 earnings · Sep 16
Rezolute Inc. Common Stock (NV)
RZLTNasdaq · USD · StocksQuote as of · Exchange session not verified$4.21
+0.96%
Today
RZLT
Loading 1D prices…
Market cap
$406.4M
Volume
1.4M
52w high
$11.4652w low
$1.07Company profile
Rezolute Inc. Common Stock (NV)
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Redwood City, CA, United States
Employees
68
Fiscal year end
0630
CIK
1509261
Session & valuation
Open$4.23
Previous close$4.17
Day high$4.36
Day low$4.08
30-day avg. volume1.3M
Outstanding shares96.3M
Diluted EPS-$0.55
Latest annual period
P/E (trailing)-7.65
P/E (forward)-6.74
Price / book3.77
Beta0.61
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| LRMRLarimar Therapeutics Inc. Common Stock | $407.2M | $0.00 | — | -$2.27 | +2.34% | Buy |
| BBOTBridgeBio Oncology Therapeutics Inc. Common Stock | $396.9M | $0.00 | — | -$4.30 | -10.87% | Buy |
| ARCTArcturus Therapeutics Holdings Inc. Common Stock | $418.7M | $82M | -80.19% | -$2.40 | +5.33% | Buy |
| GALTGalectin Therapeutics Inc. Common Stock | $394.3M | $0.00 | — | -$0.48 | +0.38% | Buy |
| BNTCBenitec Biopharma Inc. Common Stock | $418.8M | $0.00 | — | -$0.72 | -0.25% | Buy |